<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147728</url>
  </required_header>
  <id_info>
    <org_study_id>Rvision-001</org_study_id>
    <nct_id>NCT04147728</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC</brief_title>
  <acronym>Rvision-001</acronym>
  <official_title>Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in Non-small Cell Lung Cancer：An Exploratory Single-Arm Phase II Clinical Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether stereotactic radiosurgery combination with&#xD;
      Anlotinib is safe, effective in the treatment of limited brain metastases with Perilesional&#xD;
      edema in non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether stereotactic radiosurgery combination with&#xD;
      Anlotinib is safe, effective in the treatment of limited brain metastases with perilesional&#xD;
      edema in non-small cell lung cancer. The sample size is 50. Patients start to take Anlotinib&#xD;
      1 week before the MRI-based simulation，12mg/d QD，day1~14, day22~36.Edema index will be used&#xD;
      to evaluate the effectiveness of Anlotinib. The &quot;Edema index (EI)&quot; is calculated per the&#xD;
      equation of &quot;edema index= (peri-tumoral edema volume+ tumor volume)/tumor volume.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EI</measure>
    <time_frame>1 month</time_frame>
    <description>Edema Index. The &quot;Edema index (EI)&quot; is calculated per the equation of &quot;edema index= (peri-tumoral edema volume+ tumor volume)/tumor volume.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>1 year</time_frame>
    <description>Progression-free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>1 year</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>3 months</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>3 months</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iORR</measure>
    <time_frame>3 months</time_frame>
    <description>intracranial objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iPFS</measure>
    <time_frame>3 months</time_frame>
    <description>intracranial progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SRS rate</measure>
    <time_frame>1 month</time_frame>
    <description>the rate of SRS after anlotinib treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Stereotactic Body Radiation Therapy</condition>
  <arm_group>
    <arm_group_label>SRS Combination With Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic Radiosurgery Combination With Anlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.</description>
    <arm_group_label>SRS Combination With Anlotinib</arm_group_label>
    <other_name>Antiangiogenic agents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiosurgery</intervention_name>
    <description>Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases</description>
    <arm_group_label>SRS Combination With Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients voluntarily participate in this study, signed informed consent.&#xD;
&#xD;
          2. Patients pathologically diagnosed as non-small cell lung cancer, with brain metastases&#xD;
             and measurable lesions;&#xD;
&#xD;
          3. Patients aged between 18 -80 years; with expected survival time&gt;3 months.&#xD;
&#xD;
          4. Patients with no more than 5 brain metastases&#xD;
&#xD;
          5. Patients with normal organ function within 7 days prior to treatment, the following&#xD;
             criteria are met:&#xD;
&#xD;
             a) blood routine examination criteria : i) hemoglobin (HB) ≥90g/L; ii) absolute&#xD;
             neutrophil count (ANC) ≥1.5×10e9/L; iii) platelet (PLT) ≥80×10e9/L; b) biochemical&#xD;
             tests meet the following criteria: i) total bilirubin (TBIL) ≤1.5 times of upper limit&#xD;
             of normal (ULN); ii) alanine aminotransferase (ALT) and aspartate aminotransferase&#xD;
             (AST) ≤2.5 ULN, if liver metastasis occurred, ALT and AST ≤5 ULN; iii) serum&#xD;
             creatinine (Cr) ≤1.5 ULN or creatinine clearance (CCr) ≥60mL/min;&#xD;
&#xD;
          6. Female patients should agree to use contraceptives during and within 6 months after&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who had previously used antiangiogenic agents within 1 month;&#xD;
&#xD;
          2. Patients with small cell lung cancer (including small cell carcinoma and non-small&#xD;
             cell carcinoma mixed lung cancer);&#xD;
&#xD;
          3. Patient with lung squamous cell carcinoma that involved pulmonary hilar, or non-small&#xD;
             cell lung cancer with hemoptysis;&#xD;
&#xD;
          4. Patients with cerebral infarction and cerebral hemorrhage;&#xD;
&#xD;
          5. Patients without perilesional edema；&#xD;
&#xD;
          6. Patients with more than grade 2 (NCI-CTCAE v4.0) acute toxicity reaction due to any&#xD;
             previous treatment.&#xD;
&#xD;
          7. Patients with factors that affect oral medication (such as cannot swallow, chronic&#xD;
             diarrhea and intestinal obstruction, etc.);&#xD;
&#xD;
          8. Patients with visceral dissemination or severe symptoms, which could cause death in&#xD;
             short term;&#xD;
&#xD;
          9. Patients with any other severe and/or uncontrolled disease;&#xD;
&#xD;
         10. Patients who received a surgery, a biopsy or a significant traumatic injury within 1&#xD;
             month;&#xD;
&#xD;
         11. Patients with any signs or medical history of bleeding, unhealed wounds, ulcers or&#xD;
             fractures, regardless of the severity;&#xD;
&#xD;
         12. Patients underwent artery or venous thrombotic events within 2 months, such as deep&#xD;
             vein thrombosis and pulmonary embolism;&#xD;
&#xD;
         13. Patients with a history of psychotropic medicine abuse and cannot quit or have mental&#xD;
             disorders;&#xD;
&#xD;
         14. Patients with disease which will severely endanger their security and could not&#xD;
             complete this study, according to the judgement of researchers；&#xD;
&#xD;
         15. Patients who still can't tolerate SRS after anlotinib treatment, even after adding&#xD;
             mannitol, and have to receive steroid treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongqing Zhuang, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongqing Zhuang, doctor</last_name>
    <phone>13051776232</phone>
    <email>hongqingzhuang@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuxia Wang, doctor</last_name>
    <phone>15001292991</phone>
    <email>lily31415926@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology Cancer Center, Peking University Third Hospital 49# North Garden Rd.,Haidian Dist.</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongqing Zhuang, Doctor</last_name>
      <phone>13051776232</phone>
      <email>hongqingzhuang@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yuxia Wang, Doctor</last_name>
      <phone>15001292991</phone>
      <email>lily31415926@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Enmin Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yongchun Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xin Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yun Guan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>March 1, 2020</last_update_submitted>
  <last_update_submitted_qc>March 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiogenesis Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

